Corrigendum to "Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation" [Mol. Genet. Metab. 99 (2010) 62-71] (DOI:10.1016/j.ymgme.2009.08.002);Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation

Molecular Genetics and Metabolism

Volumn 99, Issue 1, 2010, Pages 62-71

  Wang, Dan ^a   Shukla, Charu ^a   Liu, Xiaoli ^b   Schoeb, Trenton R ^a   Clarke, Lorne A ^c   Bedwell, David M ^a,b   Keeling, Kim M ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Hurler syndrome; Mouse; MPS I; W402X mutation; l iduronidase

Indexed keywords

DERMATAN SULFATE; HEPARAN SULFATE; LEVO IDURONIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; FEMALE; GENE LOCUS; HISTOPATHOLOGY; HOMOZYGOSITY; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MOUSE; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALIA; MUS;

EID: 71649101421     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.12.013     Document Type: Erratum

References (53)

1. Walkley S.U. Pathogenic cascades in lysosomal disease - Why so complex?. J. Inherit. Metab. Dis. 32 (2009) 181-189
2. E.F. Neufeld, J. Muenzer, The Mucopolysaccharidoses, The Online Metabolic & Molecular Bases of Inherited Disease (www.ommbid.com), The McGraw-Hill Companies, 2001, pp. 3421-3452.
3. Futerman A.H., and Van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5 (2004) 554-565
4. Ballabio A., and Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta 1793 (2009) 684-696
5. He X., Li C.M., Simonaro C.M., Wan Q., Haskins M.E., Desnick R.J., and Schuchman E.H. Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats. Mol. Genet. Metab. 67 (1999) 106-112
6. Haskins M.E., Jezyk P.F., Desnick R.J., McDonough S.K., and Patterson D.F. Alpha-l-iduronidase deficiency in a cat: a model of mucopolysaccharidosis I. Pediatr. Res. 13 (1979) 1294-1297
7. Spellacy E., Shull R.M., Constantopoulos G., and Neufeld E.F. A canine model of human alpha-l-iduronidase deficiency. Proc. Natl. Acad. Sci. USA 80 (1983) 6091-6095
8. Shull R.M., Munger R.J., Spellacy E., Hall C.W., Constantopoulos G., and Neufeld E.F. Canine alpha-l-iduronidase deficiency. A model of mucopolysaccharidosis I. Am. J. Pathol. 109 (1982) 244-248
9. Menon K.P., Tieu P.T., and Neufeld E.F. Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I. Genomics 14 (1992) 763-768
10. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., and Neufeld E.F. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. USA 100 (2003) 1902-1907
11. Clarke L.A., Russell C.S., Pownall S., Warrington C.L., Borowski A., Dimmick J.E., Toone J., and Jirik F.R. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-l-iduronidase gene. Hum. Mol. Genet. 6 (1997) 503-511
12. Zheng Y., Rozengurt N., Ryazantsev S., Kohn D.B., Satake N., and Neufeld E.F. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol. Genet. Metab. 79 (2003) 233-244
13. Shull R.M., Helman R.G., Spellacy E., Constantopoulos G., Munger R.J., and Neufeld E.F. Morphologic and biochemical studies of canine mucopolysaccharidosis I. Am. J. Pathol. 114 (1984) 487-495
14. Garcia-Rivera M.F., Colvin-Wanshura L.E., Nelson M.S., Nan Z., Khan S.A., Rogers T.B., Maitra I., Low W.C., and Gupta P. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Res. Bull. 74 (2007) 429-438
15. Hartung S.D., Frandsen J.L., Pan D., Koniar B.L., Graupman P., Gunther R., Low W.C., Whitley C.B., and McIvor R.S. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-l-iduronidase gene. Mol. Ther. 9 (2004) 866-875
16. Russell C., Hendson G., Jevon G., Matlock T., Yu J., Aklujkar M., Ng K.Y., and Clarke L.A. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin. Genet. 53 (1998) 349-361
17. Desmaris N., Verot L., Puech J.P., Caillaud C., Vanier M.T., and Heard J.M. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. 56 (2004) 68-76
18. Graupman P., Pan D., Konair B., Hartung S., McIvor S., Whitley C., Low W., and Lam C.H. Craniofacial abnormalities in a murine knock-out model of mucopolysaccharidosis I H: a computed tomography and anatomic study. J. Craniofac. Surg. 15 (2004) 392-398
19. Liu Y., Xu L., Hennig A.K., Kovacs A., Fu A., Chung S., Lee D., Wang B., Herati R.S., Mosinger Ogilvie J., Cai S.R., and Parker Ponder K. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol. Ther. 11 (2005) 35-47
20. Pan D., Sciascia II A., Vorhees C.V., and Williams M.T. Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome. Brain Res. 1188 (2008) 241-253
21. Reolon G.K., Braga L.M., Camassola M., Luft T., Henriques J.A., Nardi N.B., and Roesler R. Long-term memory for aversive training is impaired in Idua(-/-) mice, a genetic model of mucopolysaccharidosis type I. Brain Res. 1076 (2006) 225-230
22. Braunlin E., Mackey-Bojack S., Panoskaltsis-Mortari A., Berry J.M., McElmurry R.T., Riddle M., Sun L.Y., Clarke L.A., Tolar J., and Blazar B.R. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome. Pediatr. Res. 59 (2006) 27-32
23. Jordan M.C., Zheng Y., Ryazantsev S., Rozengurt N., Roos K.P., and Neufeld E.F. Cardiac manifestations in the mouse model of mucopolysaccharidosis I. Mol. Genet. Metab. 86 (2005) 233-243
24. Kakkis E.D., McEntee M.F., Schmidtchen A., Neufeld E.F., Ward D.A., Gompf R.E., Kania S., Bedolla C., Chien S.L., and Shull R.M. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. 58 (1996) 156-167
25. Hopwood J.J., Muller V., Smithson A., and Baggett N. A fluorometric assay using 4-methylumbelliferyl alpha-l-iduronide for the estimation of alpha-l-iduronidase activity and the detection of Hurler and Scheie syndromes. Clin. Chim. Acta 92 (1979) 257-265
26. Birkenmeier E.H., Davisson M.T., Beamer W.G., Ganschow R.E., Vogler C.A., Gwynn B., Lyford K.A., Maltais L.M., and Wawrzyniak C.J. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J. Clin. Invest. 83 (1989) 1258-1266
27. Wendeler M., and Sandhoff K. Hexosaminidase assays. Glycoconj. J. (2008)
28. Whitley C.B., Ridnour M.D., Draper K.A., Dutton C.M., and Neglia J.P. Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin. Chem. 35 (1989) 374-379
29. de Jong J.G., Wevers R.A., and Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin. Chem. 38 (1992) 803-807
30. Kobayashi H., Carbonaro D., Pepper K., Petersen D., Ge S., Jackson H., Shimada H., Moats R., and Kohn D.B. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol. Ther. 11 (2005) 776-789
31. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
32. Scott H.S., Bunge S., Gal A., Clarke L.A., Morris C.P., and Hopwood J.J. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum. Mutat. 6 (1995) 288-302
33. Peltz S.W., Brown A.H., and Jacobson A. MRNA destabilization triggered by premature translational termination depends on at least three cis-acting sequence elements and one trans-acting factor. Genes Dev. 7 (1993) 1737-1754
34. Menon K.P., and Neufeld E.F. Evidence for degradation of mRNA encoding alpha-l-iduronidase in Hurler fibroblasts with premature termination alleles. Cell. Mol. Biol. (Noisy-le-Grand) 40 (1994) 999-1005
35. Chung S., Ma X., Liu Y., Lee D., Tittiger M., and Ponder K.P. Effect of neonatal administration of a retroviral vector expressing alpha-l-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol. Genet. Metab. 90 (2007) 181-192
36. Ma X., Liu Y., Tittiger M., Hennig A., Kovacs A., Popelka S., Wang B., Herati R., Bigg M., and Ponder K.P. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol. Ther. 15 (2007) 889-902
37. Woloszynek J.C., Coleman T., Semenkovich C.F., and Sands M.S. Lysosomal dysfunction results in altered energy balance. J. Biol. Chem. 282 (2007) 35765-35771
38. Kmiec E.B. Targeted gene repair - in the arena. J. Clin. Invest. 112 (2003) 632-636
39. Linde L., and Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet. 24 (2008) 552-563
40. Keeling K.M., and Bedwell D.M. Pharmacological suppression of premature stop mutations that cause genetic diseases. Curr. Pharmacogenomics 3 (2005) 259-269
41. Keeling K.M., Du M., and Bedwell D.M. Therapies of nonsense-associated diseases. In: Maquat L.E. (Ed). Nonsense-Mediated mRNA Decay (2006), Landes Bioscience, Georgetown, Texas 121-136
42. Keeling K.M., Brooks D.A., Hopwood J.J., Li P., Thompson J.N., and Bedwell D.M. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-l-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum. Mol. Genet. 10 (2001) 291-299
43. Keeling K.M., and Bedwell D.M. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J. Mol. Med. 80 (2002) 367-376
44. Brooks D.A., Muller V.J., and Hopwood J.J. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol. Med. 12 (2006) 367-373
45. Aldenhoven M., Boelens J.J., and De Koning T.J. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol. Blood Marrow Transplant. 14 (2008) 485-498
46. Miebach E. Enzyme replacement therapy in mucopolysaccharidosis type I. Acta Paediatr. 1 Suppl. 94 (2005) 58-60 (discussion 57)
47. Strausbaugh L.J., and Brinker G.S. Effect of osmotic blood-brain barrier disruption on gentamicin penetration into the cerebrospinal fluid and brains of normal rabbits. Antimicrob. Agents Chemother. 24 (1983) 147-150
48. Smith A.L., Daum R.S., Siber G.R., Scheifele D.W., and Syriopoulou V.P. Gentamicin penetration into cerebrospinal fluid in experimental Haemophilus influenzae meningitis. Antimicrob. Agents Chemother. 32 (1988) 1034-1039
49. Newman R.L., and Holt R.J. Intrathecal gentamicin in treatment of ventriculitis in children. Br. Med. J. 2 (1967) 539-542
50. McCracken Jr. G.H., Chrane D.F., and Thomas M.L. Pharmacologic evaluation of gentamicin in newborn infants. J. Infect. Dis. 124 Suppl. 124 (1971) 214
51. Lopez-Samblas A.M., Torres C.L., Wang H., Feuer W.J., and Goldberg R.N. Effectiveness of a gentamicin dosing protocol based on postconceptional age: comparison to published neonatal guidelines. Ann. Pharmacother. 26 (1992) 534-538
52. Ho K.K., Bryson S.M., Thiessen J.J., Greenberg M.L., Einarson T.R., and Leson C.L. The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients. Pharmacotherapy 15 (1995) 754-764
53. Chang Y.F., Imam J.S., and Wilkinson M.F. The nonsense-mediated decay RNA surveillance pathway. Ann. Rev. Biochem. 76 (2007) 51-74